SCHEMBL8965254

SCHEMBL8965254

O=C(c1cncc(NCc2ccccc2)c1)c1cccc(N2CCCNCC2)n1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCA P17252 2/20 0.48
PRKCQ Q04759 2/20 0.48
PRKCD Q05655 2/20 0.48
PIM2 Q9P1W9 1/20 0.41
NTRK1 P04629 2/20 0.41
HSD17B14 Q9BPX1 1/20 0.41
CYP11B2 P19099 1/20 0.40
ROCK1 Q13464 1/20 0.39
CHRNB2 P17787 1/20 0.39
CHRNA4 P43681 1/20 0.39
STAT6 P42226 1/20 0.39
CHEK1 O14757 1/20 0.39
MAOB P27338 2/20 0.39
HTR6 P50406 2/20 0.39
ACHE P22303 1/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
HRH4 Q9H3N8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8965234 0.85 PRKCA (0.51) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL8965230 0.85 PRKCA (0.51) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL8965541 0.85 PRKCA (0.52) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL9013301 0.83 PRKCQ (0.61) PRKCAPRKCQPRKCDPIM2NTRK1
SCHEMBL8963649 0.82 PRKCA (0.53) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL8964332 0.81 PRKCA (0.52) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL8965021 0.80 PIM2 (0.52) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL15930671 0.78 PRKCA (0.50) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL8964909 0.78 PRKCA (0.55) PRKCAPRKCQPRKCDPIM2HSD17B14
SCHEMBL8964367 0.78 PRKCA (0.52) PRKCAPRKCQPRKCDPIM2HSD17B14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221334-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-08-07 US disclosed
US-8741931-B2 Kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED 2014-06-03 US disclosed
US-20120214799-A1 KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-08-23 US disclosed
US-8188071-B2 Amino substituted pyridines as potent kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140221334-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 PRKCA 25/4885PRKCQ 38/4885PRKCD 120/4885
US-20120214799-A1 KINASE INHIBITORS MAP3K20, MAP3K1, MAP3K6 PRKCA 25/4885PRKCQ 38/4885PRKCD 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.